NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02340221,A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy,https://clinicaltrials.gov/study/NCT02340221,SANDPIPER,TERMINATED,"This international, multicenter, randomized, double-blinded, placebo-controlled study is designed to compare the efficacy and safety of taselisib + fulvestrant with that of placebo + fulvestrant in postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative, oncogene that encodes for phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3CA)-mutant, unresectable, locally advanced or metastatic breast cancer after recurrence or progression during or after an aromatase inhibitor (AI) therapy. There will be a 2:1 randomization to the taselisib arm versus the placebo arm. Enrollment will be enriched for participants with PIK3CA mutant tumors via central testing. The anticipated duration of the study is approximately 3.5 years.",YES,Breast Cancer,DRUG: Taselisib|DRUG: Placebo|DRUG: Fulvestrant,"Progression-Free Survival (PFS) as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) at Primary Analysis, PFS was defined as the time from randomization to disease progression as determined by the investigator with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression., From randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to the 15 Oct 2017 data cutoff, approximately 2.5 years)|PFS as Assessed by Investigator Using RECIST v1.1 at Final Analysis, PFS was defined as the time from randomization to disease progression as determined by the investigator with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression., From randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to approximately 6.2 years)","Percentage of Participants With Objective Response (Partial Response [PR] Plus Complete Response [CR]), as Assessed Using RECIST v.1.1 at Primary Analysis, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions)., From randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to the 15 Oct 2017 data cutoff, approximately 2.5 years)|Percentage of Participants With Objective Response (PR Plus CR), as Assessed Using RECIST v.1.1 at Final Analysis, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions)., From randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to approximately 6.2 years)|Overall Survival (OS) at Primary Analysis, OS was defined as the time from the date of randomization to the date of death due to any cause., From randomization up to death from any cause (up to the 15 Oct 2017 data cutoff, approximately 2.5 years)|OS at Final Analysis, OS was defined as the time from the date of randomization to the date of death due to any cause., From randomization up to death from any cause (up to approximately 6.2 years)|Percentage of Participants With Clinical Benefit, as Assessed According to RECIST v1.1 at Primary Analysis, Clinical benefit was defined as objective response (PR+CR), or no disease progression lasting for more than or equal to (\>/=) 24 weeks since randomization. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions). Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression., From randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to the 15 Oct 2017 data cutoff, approximately 2.5 years)|Percentage of Participants With Clinical Benefit, as Assessed According to RECIST v1.1 at Final Analysis, Clinical benefit was defined as objective response (PR+CR), or no disease progression lasting for more than or equal to (\>/=) 24 weeks since randomization. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions). Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression., From randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to approximately 6.2 years)|Duration of Objective Response, as Assessed by Investigator Using RECIST v1.1 at Primary Analysis, Duration of objective response: the time from the first tumor assessment that supported the participant's objective response (CR or PR, whichever was first recorded) to first documented disease progression or death due to any cause, whichever occurred first. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Disease progression: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression., Time from the first occurrence of a documented objective response to the time of the first documented disease progression or death from any cause, whichever occurs earlier (up to the 15 Oct 2017 data cutoff, approximately 2.5 years)|Duration of Objective Response, as Assessed by Investigator Using RECIST v1.1 at Final Analysis, Duration of objective response: the time from the first tumor assessment that supported the participant's objective response (CR or PR, whichever was first recorded) to first documented disease progression or death due to any cause, whichever occurred first. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Disease progression: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression., Time from the first occurrence of a documented objective response to the time of the first documented disease progression or death from any cause, whichever occurs earlier (up to approximately 6.2 years)|PFS as Assessed by Blinded Independent Central Review (BICR) Using RECIST v1.1 at Primary Analysis, PFS was defined as the time from randomization to disease progression as determined by BICR with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression., From randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to the 15 Oct 2017 data cutoff, approximately 2.5 years)|PFS as Assessed by BICR Using RECIST v1.1 at Final Analysis, PFS was defined as the time from randomization to disease progression as determined by BICR with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression., From randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to approximately 6.2 years)|Percentage of Participants With Adverse Events at Primary Analysis, An adverse event was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution., From randomization up to the 15 Oct 2017 data cutoff, approximately 2.5 years.|Percentage of Participants With Adverse Events at Final Analysis, An adverse event was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution., From randomization up to approximately 6.2 years|Maximum Observed Plasma Concentration (Cmax) of Taselisib, 1 to 4 hours (hrs) post-dose on Cycle (C) 1, Day (D) 1; 0 to 3 hrs pre-dose and 2 to 6 hrs post dose on Cycle 2, Day 1 (each cycle=28 days)|Minimum Observed Plasma Concentration (Cmin) of Taselisib, 1 to 4 hrs post-dose on Cycle 1, Day 1; 0 to 3 hrs pre-dose and 2 to 6 hrs post dose on Cycle 2, Day 1; 0 to 3 hrs pre-dose on Cycle 6, Day 1 (each cycle=28 days)|Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) Score, The EORTC QLQ-C30 consists of 30 questions that comprise aspects of participant's functioning assessment (physical, emotional, role, cognitive, and social); symptom scales (fatigue; nausea, vomiting, and pain; the global health/quality of life \[QoL\]); and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhoea, and financial difficulties), within a recall period of ""the past week."" Most questions used a 4-point scale (1=Not at all to 4=Very much; two questions used a 7-point scale (1=Very poor to 7=Excellent). Scores were averaged and transformed to a 0-100 scale; a higher score for Global Qol/functional scales=better level of functioning; a higher score for symptom scale=greater degree of symptoms., Baseline, C2D1 up to C7D1 (each cycle=28 days)|Change From Baseline in Modified EORTC Quality of Life Questionnaire Breast Cancer Module 23 (QLQ-BR23) Score, EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of functional scales (body image, sexual enjoyment, sexual functioning, future perspective \[FP\]) and symptom scales (systemic side effects \[SE\], upset by hair loss, arm symptoms, breast symptoms). Questions used a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores were averaged and transformed to a 0-100 scale. Higher scores for the functional scales indicated a higher/better level of functioning/healthy functioning. Higher scores for the symptom scales indicated worse symptoms., Baseline, C2D1 up to C7D1 (each cycle=28 days)",,Hoffmann-La Roche,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,631,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",GO29058|2014-003185-25,2015-04-09,2021-06-29,2021-06-29,2015-01-16,2019-01-25,2022-07-12,"Arizona Oncology, Tucson, Arizona, 85704, United States|Arizona Oncology Associates, P.C., Tucson, Arizona, 85710, United States|Georgia Cancer Specialists - Northside, Atlanta, Georgia, 30341, United States|Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital, Marietta, Georgia, 30060, United States|Ingalls Hospital, Harvey, Illinois, 60426, United States|Maryland Oncology Hematology, Rochville, Maryland, 20850, United States|Dana Farber Can Ins, Boston, Massachusetts, 02215, United States|Mercy Hospitals East Communities d/b/a Mercy Hospital St. Louis, Saint Louis, Missouri, 63141, United States|MSKCC at Basking Ridge, Basking Ridge, New Jersey, 07920, United States|John Theurer Cancer Ctr at Hackensack Univ Medical Ctr, Hackensack, New Jersey, 07601, United States|Memorial Sloan-Kettering; Cancer Center, Commack, New York, 11725, United States|Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering; at Westchester, Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, 11553, United States|Oregon Health & Science University; Knight Cancer Institute, Community Hematology Oncology, Beaverton, Oregon, 97006, United States|Pinnacle Health, Harrisburg, Pennsylvania, 17110, United States|Liverpool Hospital; Cancer Therapy Centre, Liverpool, New South Wales, 2170, Australia|Macquarie University Hospital, Macquarie Park, New South Wales, 2109, Australia|Newcastle Mater Misericordiae Hospital; Oncology, Waratah, New South Wales, 2298, Australia|Mater Hospital; Oncology, Brisbane, Queensland, 4101, Australia|Austin Hospital; Medical Oncology, Heidelberg, Victoria, 3084, Australia|Sunshine Hospital; Oncology Research, St Albans, Victoria, Australia|St John of God Murdoch Hospital; Oncology West, Murdoch, Western Australia, 6150, Australia|Lkh-Univ. Klinikum Graz; Klinik Für Innere Medizin I, Graz, 8036, Austria|Tiroler Landeskrankenanstalten Ges.M.B.H.; Abt. Für Gynäkologie, Innsbruck, 6020, Austria|Ordensklinikum Linz Barmherzige Schwestern; Abt. fur Innere Medizin 1, Linz, 4010, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin I, Wien, 1090, Austria|University Clinical Center of the Republic of Srpska, Banja Luka, 78000, Bosnia and Herzegovina|Clinic of Oncology, University Clinical Center Sarajevo, Sarajevo, 7100, Bosnia and Herzegovina|Complex Oncological Center - Plovdiv, EOOD, Plovdiv, 4004, Bulgaria|MHAT Nadezhda, Sofia, 1330, Bulgaria|SHATO - Sofia, Sofia, 1756, Bulgaria|SHATOD Dr. Marko Antonov Markov-Varna, EOOD, Varna, 9010, Bulgaria|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre, Vancouver, British Columbia, V5Z 4E6, Canada|Grand River Hospital, Kitchener, Ontario, N2G 1G3, Canada|The Ottawa Hospital Cancer Centre; Oncology, Ottawa, Ontario, K1H 8L6, Canada|Sunnybrook Health Science Centre, Toronto, Ontario, M4N 3M5, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, H3T 1E2, Canada|Hospital Du Saint-Sacrement, Quebec City, Quebec, G1S 4L8, Canada|the First Hospital of Jilin University, Changchun, 130021, China|Jilin Cancer Hospital, Changchun, 132013, China|Jiangsu Cancer Hospital, Nanjing City, 211100, China|Fudan University Shanghai Cancer Center, Shanghai City, 200120, China|Zhejiang Cancer Hospital, Zhejiang, 310022, China|Clinica del Country, Bogota, 11001, Colombia|Oncomedica S.A., Monteria, 230002, Colombia|University Hospital; Oncology and Radiotherapy, Hradec Kralove, 500 05, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, 779 00, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, 128 08, Czechia|KYS Sadesairaala; Syopatautien poliklinikka, Kuopio, 70210, Finland|Turku Uni Central Hospital; Oncology Clinics, Turku, 20520, Finland|Centre Jean Perrin; Hopital De Semaine, Clermont-Ferrand, 63011, France|Centre Georges François Leclerc; Service Pharmacie, Bp 77980, Dijon, 21000, France|Hopital Prive Drome Ardeche; Chir 2A 2B, Guilherand Granges, 07500, France|CHD Vendée, La Roche Sur Yon, 85025, France|Hopital Dupuytren; Oncologie Medicale, Limoges, 87042, France|Institut régional du Cancer Montpellier, Montpellier, 34298, France|Institut Curie; Oncologie Medicale, Paris, 75231, France|Ch Lyon Sud; Onco Secteur Jules Courmont, Pierre Benite, 69495, France|Pole de Cancerologie Prive Strasbourgeois, Strasbourg, 67000, France|Centre Alexis Vautrin; Oncologie Medicale, Vandoeuvre-les-nancy, 54519, France|Hochwaldkrankenhaus; Abt.Gynäkologie Geburtshilfe u.Senologie, Bad Nauheim, 61231, Germany|Praxisklinik Krebsheilkunde für Frauen / Brustzentrum (Dres. Kittel/Klare), Berlin, 10367, Germany|Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, 10707, Germany|Universitätsklinikum Essen; Zentrum Für Frauenheilkunde, Essen, 45122, Germany|Kooperatives Mammazentrum Hamburg Krankenhaus Jerusalem, Hamburg, 20357, Germany|Klinikum der Universität München; Frauenklinik - Onkologie II, München, 80337, Germany|Klinikum Mutterhaus der Borromäerinnen, Innere Medizin I, Trier, 54290, Germany|Alexandras General Hospital of Athens; Oncology Department, Athens, 115 28, Greece|IASO General Hospital of Athens, Athens, 155 62, Greece|Univ General Hosp Heraklion; Medical Oncology, Heraklion, 711 10, Greece|University Hospital of Patras Medical Oncology, Patras, 265 04, Greece|Euromedical General Clinic of Thessaloniki; Oncology Department, Thessaloniki, 546450, Greece|Papageorgiou General Hospital; Medical Oncology, Thessaloniki, 564 29, Greece|Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica, Napoli, Campania, 80131, Italy|ARCISPEDALE S. MARIA NUOVA - REGGIO EMILIA; Struttura Semplice Coordinamento Breast Unit Integrata, Reggio Emilia, Emilia-Romagna, 42100, Italy|A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia, Udine, Friuli-Venezia Giulia, 33100, Italy|IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A, Genova, Liguria, 16132, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, 20141, Italy|Centro Catanese Di Oncologia; Oncologia Medica, Catania, Sicilia, 95126, Italy|Azienda Ospedaliero-Universitaria Careggi; SOD Radioterapia, Firenze, Toscana, 50134, Italy|Azienda USL 9 Grosseto; Dipartimento Politiche del Farmaco, Grosseto, Toscana, 58100, Italy|Azienda usl 5 Di Pisa-Ospedale Di Pontedera;U.O. Oncologia, Pontedera, Toscana, 56025, Italy|AZ. Usll12 Veneziana-Ospedale Dell'angelo;Oncologia Medica, Mestre, Veneto, 30174, Italy|Inje university Haeundae Paik Hospital, Busan, 48108, Korea, Republic of|Chungbuk National University Hospital, Cheongju-si, 28644, Korea, Republic of|National Cancer Center, Goyang-si, 10408, Korea, Republic of|Korea University Anam Hospital, Seoul, 02841, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Ulsan University Hosiptal, Ulsan, 44033, Korea, Republic of|Iem-Fucam, D.f., 04980, Mexico|Instituto Nacional De Cancerologia; Oncology; Tumores Mamarios, Distrito Federal, 14000, Mexico|Consultorio de Medicina Especializada; Dentro de Condominio San Francisco, Mexico City, 03100, Mexico|Hospital San Jose Del Tec. de Monterrey; Oncology, Monterrey, 64020, Mexico|Oaxaca Site Management Organization, Oaxaca, 68000, Mexico|Medisch Centrum Alkmaar, Alkmaar, 1815 JD, Netherlands|Ziekenhuis Rijnstate, Arnhem, 6815 AD, Netherlands|Instituto Nacional de Enfermedades Neoplasicas, Lima, Lima 34, Peru|Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional, Lima, Lima 41, Peru|Oncocenter Peru S.A.C.; Oncosalud, Lima, Lima 41, Peru|Instituto Regional de Enfermedades Neoplasicas - IREN Norte, Trujillo, 13014, Peru|Bialostockie Centrum Onkologii; Oddzial Onkologii Klinicznej, Bialystok, 15-027, Poland|Centrum Onkologii w Bydgoszczy; Oddzial Kliniczny Onkologii, Bydgoszcz, 85-796, Poland|Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdansk, 80-214, Poland|Przychodnia Lekarska KOMED, Roman Karaszewski, Konin, 62-500, Poland|Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii, Kraków, 30-688, Poland|Woj.Wielospecjalistyczne Centrum Onkologii i Traumatologii; Oddz.Hematologii Pododz.Chemioterapii, Lodz, 93-513, Poland|Centrum Onkologii Ziemi LUBELSKIEJ im. Sw Jana z Dukli, I oddz. Chemioterapii, Lublin, 20-090, Poland|Zachodniopomorskie Centrum Onkologii, Osrodek Innowacyjnosci, Rozwoju i Badan Klinicznych, Szczecin, 71-730, Poland|Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Klinika Nowotworów Piersi i Chirurgii, Warszawa, 02-781, Poland|Wojewodzki Szpital Specjalistyczny; Osrodek Badawczo-Rozwojowy, Oddzial Chemioterapii, Wroclaw, 51-124, Poland|Hospital Garcia de Orta; Servico de Oncologia Medica, Almada, 2801-951, Portugal|IPO de Lisboa; Servico de Oncologia Medica, Lisboa, 1099-023, Portugal|Hospital da Luz; Departamento de Oncologia Medica, Lisboa, 1500-650, Portugal|Hospital de Santa Maria; Servico de Oncologia Medica, Lisboa, 1649-035, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, 4200-072, Portugal|Institut of Oncology Al. Trestioreanu Bucharest; Oncology Department, Bucuresti, 022328, Romania|Prof. Dr. I. Chiricuta Institute of Oncology, Cluj Napoca, 400015, Romania|Oncology Center Sf. Nectarie, Craiova, 200347, Romania|Euroclinic Center of Oncology SRL, Iasi, 700106, Romania|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, 143423, Russian Federation|Regional Clinical Oncology Dispensary; Surgery Dept, Thoracic, Arkhangelsk, 163045, Russian Federation|Ivanovo Regional Oncology Dispensary, Ivanovo, 153040, Russian Federation|Clinical Oncology Dispensary of Ministry of Health of Tatarstan, Kazan, 420029, Russian Federation|State Inst. Of Healthcare Orenburg Regional Clinical Oncology Dis, Orenburg, 460021, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, 197758, Russian Federation|Institute for Onc/Rad Serbia, Belgrade, 11000, Serbia|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, 15706, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Majadahonda, Madrid, 28222, Spain|Hospital Universitario de Canarias;servicio de Oncologia, La Laguna, Tenerife, 38320, Spain|Hospital de Cruces; Servicio de Oncologia, Bilbao, Vizcaya, 48903, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, 08036, Spain|Centro Oncologico MD Anderson Internacional; Servicio de Oncologia, Madrid, 28033, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, 28034, Spain|HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia, Madrid, 28050, Spain|Fundación IVO, Valencia, 46980, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, 50009, Spain|Uni Hospital Linkoeping; Dept. of Oncology, Linköping, 58185, Sweden|Sodersjukhuset; Onkologkliniken, Stockholm, 118 83, Sweden|Akademiska sjukhuset, Onkologkliniken, Uppsala, 751 85, Sweden|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei City, 11259, Taiwan|VETERANS GENERAL HOSPITAL; Department of General Surgery, Taipei, 00112, Taiwan|National Taiwan Uni Hospital; General Surgery, Taipei, 100, Taiwan|Mackay Memorial Hospital; Dept of Surgery, Taipei, 104, Taiwan|Department of Surgery, King Chulalongkorn Memorial Hospital, Bangkok, 10330, Thailand|Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok, 10400, Thailand|Maharaj Nakorn Chiang Mai Hospital; Department of Surgery/Head Neck and Breast Unit; Clinical Trial, Chiang Mai, 50200, Thailand|Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology, Adana, 01230, Turkey|Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department, Edirne, 22770, Turkey|Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology, Istanbul, 34300, Turkey|Ege Uni Medical Faculty; Oncology Dept, Izmir, 35100, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sihhiye/Ankara, 06230, Turkey","Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/21/NCT02340221/Prot_SAP_000.pdf"
